citalopram has been researched along with Alzheimer Disease in 81 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Alzheimer Disease: A degenerative disease of the BRAIN characterized by the insidious onset of DEMENTIA. Impairment of MEMORY, judgment, attention span, and problem solving skills are followed by severe APRAXIAS and a global loss of cognitive abilities. The condition primarily occurs after age 60, and is marked pathologically by severe cortical atrophy and the triad of SENILE PLAQUES; NEUROFIBRILLARY TANGLES; and NEUROPIL THREADS. (From Adams et al., Principles of Neurology, 6th ed, pp1049-57)
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results provide novel information on the efficacy of sertraline and escitalopram in the treatment of apathy and depression, respectively, in patients with AD." | 9.34 | The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP). ( Abe, K; Hishikawa, N; Matsumoto, N; Nomura, E; Ohta, Y; Omote, Y; Sasaki, R; Tadokoro, K; Takemoto, M; Tsunoda, K; Yamashita, T, 2020) |
| "To assess efficacy and safety of citalopram compared to quetiapine and olanzapine for the treatment of agitation in patients with Alzheimer disease (AD)." | 9.24 | Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. ( Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017) |
| "The aim was to determine the relationship between (R) and (S)-citalopram enantiomer exposure (AUC(0,24 h)) and therapeutic response in agitated individuals greater than 60 years old with Alzheimer's dementia (AD)." | 9.22 | R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. ( Bies, R; Devanand, DP; Drye, LT; Ho, T; Lyketsos, C; Mintzer, JE; Mulsant, BH; Munro, CA; Pollock, BG; Porsteinsson, AP; Schantz, O; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| " The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed." | 9.22 | Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, CM; Mintzer, J; Mulsant, BH; Munro, CA; Newell, JA; Pawluczyk, S; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rein, L; Rosenberg, PB; Schneider, LS; Shade, D; Weintraub, D; Yesavage, J, 2016) |
| "The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease." | 9.19 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014) |
| "In the current study, we investigated the protective role of citalopram against cognitive decline, impaired mitochondrial dynamics, defective mitochondrial biogenesis, defective autophagy, mitophagy and synaptic dysfunction in APP transgenic mouse model of Alzheimer's disease (ad)." | 8.02 | Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease. ( Bunquin, LE; Kshirsagar, S; Morton, H; Reddy, AP; Reddy, PH; Sawant, N; Yin, X, 2021) |
| "Citalopram patients were more likely than placebo patients to be a late responder (18% versus 8% on CGIC, Fisher's exact p = 0." | 6.80 | Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2015) |
| "These results provide novel information on the efficacy of sertraline and escitalopram in the treatment of apathy and depression, respectively, in patients with AD." | 5.34 | The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP). ( Abe, K; Hishikawa, N; Matsumoto, N; Nomura, E; Ohta, Y; Omote, Y; Sasaki, R; Tadokoro, K; Takemoto, M; Tsunoda, K; Yamashita, T, 2020) |
| "To assess efficacy and safety of citalopram compared to quetiapine and olanzapine for the treatment of agitation in patients with Alzheimer disease (AD)." | 5.24 | Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia. ( Chiriac, IM; Ettorre, E; Viscogliosi, G, 2017) |
| "To investigate the efficacy and tolerability of escitalopram in the treatment of depression in AD." | 5.24 | The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects. ( An, H; Choi, B; Han, SH; Hong, CH; Kim, DH; Kim, SY; Park, KW; Yang, DW, 2017) |
| "The aim was to determine the relationship between (R) and (S)-citalopram enantiomer exposure (AUC(0,24 h)) and therapeutic response in agitated individuals greater than 60 years old with Alzheimer's dementia (AD)." | 5.22 | R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation. ( Bies, R; Devanand, DP; Drye, LT; Ho, T; Lyketsos, C; Mintzer, JE; Mulsant, BH; Munro, CA; Pollock, BG; Porsteinsson, AP; Schantz, O; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| "While dosage constraints must be considered because of citalopram's adverse effect profile, this agent's overall therapeutic effects in patients with Alzheimer's disease and agitation, in addition to efficacy for agitation/aggression, included reductions in the frequency of irritability, anxiety, and delusions; among patients who had these symptoms at week 9, they included a reduction in the severity of hallucinations but an increase in the severity of sleep/nighttime behavior disorders." | 5.22 | Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study. ( Devanand, DP; Drye, LT; Frangakis, C; Leonpacher, AK; Lyketsos, CG; Makino, KM; Mintzer, JE; Munro, CA; Newell, JA; Peters, ME; Pollock, BG; Porsteinsson, AP; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| " The authors assessed the heterogeneity of response to citalopram in the Citalopram for Agitation in Alzheimer Disease (CitAD) study to identify individuals who may be helped or harmed." | 5.22 | Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, CM; Mintzer, J; Mulsant, BH; Munro, CA; Newell, JA; Pawluczyk, S; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rein, L; Rosenberg, PB; Schneider, LS; Shade, D; Weintraub, D; Yesavage, J, 2016) |
| "The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease." | 5.19 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014) |
| "In the current study, we investigated the protective role of citalopram against cognitive decline, impaired mitochondrial dynamics, defective mitochondrial biogenesis, defective autophagy, mitophagy and synaptic dysfunction in APP transgenic mouse model of Alzheimer's disease (ad)." | 4.02 | Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease. ( Bunquin, LE; Kshirsagar, S; Morton, H; Reddy, AP; Reddy, PH; Sawant, N; Yin, X, 2021) |
| "We performed in vivo microdialysis and in vivo 2-photon imaging to assess changes in brain interstitial fluid (ISF) Aβ and Aβ plaque size over time, respectively, in the APP/presenilin 1 mouse model of Alzheimer disease treated with vehicle or escitalopram." | 3.96 | Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model. ( Cirrito, JR; Davis, TA; Doherty, BM; Gardiner, WD; King, D; Lee, JM; Sheline, YI; Wallace, CE; Yan, P; Yuede, CM, 2020) |
| "To ascertain the impact of treatment with citalopram on irritability, apathy, delusions, and hallucinations in nondepressed behaviorally disturbed Alzheimer's disease (AD) patients." | 3.75 | Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease. ( Hynan, LS; Siddique, H; Weiner, MF, 2009) |
| "Primary outcome is the Modified Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (mADCS-CGIC)." | 2.90 | Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial. ( Avramopoulos, D; Baksh, SN; Devanand, DP; Drye, LT; Ehrhardt, S; Ismail, Z; Lyketsos, CG; Mintzer, J; Munro, CA; Pollock, BG; Porsteinsson, AP; Rajji, TK; Rosenberg, PB; Schneider, LS; Shade, DM, 2019) |
| "Citalopram patients were more likely than placebo patients to be a late responder (18% versus 8% on CGIC, Fisher's exact p = 0." | 2.80 | Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2015) |
| " In healthy human volunteers, citalopram's effects on Aβ production and Aβ concentrations in cerebrospinal fluid (CSF) were measured prospectively using stable isotope labeling kinetics, with CSF sampling during acute dosing of citalopram." | 2.79 | An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice. ( Bateman, RJ; Chott, R; Cirrito, JR; Ficker, WD; Fisher, JR; Frederiksen, C; Grzelak, MV; Jasielec, MS; Lee, JM; Mintun, MA; Morris, JC; Sheline, YI; Swarm, R; West, T; Xiong, C; Yan, P; Yarasheski, K, 2014) |
| "Citalopram at 30 mg/day was associated with improvement in agitation in patients with AD but was also associated with QT prolongation." | 2.79 | Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial. ( Devanand, DP; Drye, LT; Frangakis, C; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Spragg, D; Weintraub, D; Yesavage, J, 2014) |
| "The citalopram for agitation in Alzheimer's disease (CitAD) study was designed to evaluate the potential of citalopram to ameliorate these symptoms." | 2.77 | Citalopram for agitation in Alzheimer's disease: design and methods. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Weintraub, D; Yesavage, J, 2012) |
| "Antipsychotics are frequently used to treat psychosis, aggression and agitation in patients with Alzheimer's disease (AD), but safety warnings abound." | 2.76 | Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study. ( Barak, Y; Paleacu, D; Plopski, I; Tadger, S, 2011) |
| "Escitalopram was efficacious and safe for the treatment of dAD in this study." | 2.72 | An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD). ( Lee, HB; Lyketsos, CG; Rao, V; Rosenberg, PB; Rosenblatt, A; Spiro, JR, 2006) |
| "In patients with Alzheimer's disease and vascular dementia, there are symptoms not only of cognitive impairment but also of emotional disturbance." | 2.67 | Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia. ( Gottfries, CG; Nyth, AL, 1991) |
| "Neuropsychiatric symptoms are common in Alzheimer's disease (AD) and other neurodegenerative disorders." | 2.52 | Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease. ( Cummings, J; Zhong, K, 2015) |
| "Neuropsychiatric symptoms (NPS) in Alzheimer's disease (AD) are associated with significant negative outcomes for patients and their caregivers." | 2.52 | Advancements in the treatment of agitation in Alzheimer's disease. ( Antonsdottir, IM; Keltz, M; Porsteinsson, AP; Smith, J, 2015) |
| "Treatment with Citalopram appears to have little effect on Aβ generation in fADPSEN1 cells, but our findings suggest that treatment can significantly increase non-amyloidogenic AβPP processing and reduce oxidative stress." | 1.72 | The effect of citalopram treatment on amyloid-β precursor protein processing and oxidative stress in human hNSC-derived neurons. ( Aldred, S; Crowe, JA; Dunleavy, C; Elsworthy, RJ; Fisher, E; Hill, EJ; King, MC; Ludlam, A; Parri, HR, 2022) |
| "Citalopram was the most widely used antidepressant medication (32." | 1.62 | Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study. ( Camargos, EF; Machado, FV; Martini, LLL; Novaes, MRCG; Oliveira, LF, 2021) |
| "Depression is associated with an increased risk of Alzheimer's disease." | 1.48 | Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression. ( Bartels, C; Ehrenreich, H; Schneider, A; Wagner, M; Wolfsgruber, S, 2018) |
| "In the Citalopram for Agitation in Alzheimer's Disease (CitAD) randomized controlled trial, the new method identifies substantially larger groups of highly benefited patients, many of whom are missed by the standard method." | 1.46 | Characterizing Highly Benefited Patients in Randomized Clinical Trials. ( Charu, V; Drye, LT; Frangakis, CE; Lyketsos, CG; Rein, L; Rosenberg, PB; Schneider, LS; Shade, D, 2017) |
| "Escitalopram treatment in patients with MNCD-AD or ScVMNCD led to an increase of plasma BDNF concentrations and as a result to a decrease of cognitive, depressive, and anxiety symptom severity." | 1.43 | Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study. ( Cherednichenko, NV; Levada, OA; Trailin, AV; Troyan, AS, 2016) |
| " A nonlinear mixed effects population pharmacokinetic modeling approach was used to describe the pharmacokinetics of R- and S-citalopram and their primary metabolite (desmethylcitalopram)." | 1.43 | A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation. ( Akil, A; Avramopoulos, D; Bies, RR; Devanand, DP; Lyketsos, CG; Mintzer, JE; Pollock, BG; Porsteinsson, AP; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2016) |
| "Severe myoclonus and increased restlessness are hallmarks of the disorder." | 1.36 | A perfect storm in the emergency department. ( Wijdicks, EF; Yee, AH, 2010) |
| "Hypersexuality in Alzheimer's disease (AD) has been rarely investigated." | 1.35 | Effect of citalopram in treating hypersexuality in an Alzheimer's disease case. ( Bruno, G; Lenzi, GL; Talarico, G; Tosto, G, 2008) |
| "Seven probable Alzheimer's disease patients and seven demographically comparable controls underwent two positron emission tomography (PET) glucose metabolism scans, after administration of a saline placebo infusion (Day 1) and after citalopram (40 mg, IV, Day 2)." | 1.35 | Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. ( Chaly, T; Dhawan, V; Eidelberg, D; Hermann, CR; Kramer, E; Ma, Y; Smith, GS, 2009) |
| "Comorbid depression of Alzheimer's disease (AD) is a common mood disorder in the elderly and a broad spectrum of antidepressants have been used for its treatment." | 1.33 | Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro. ( Bjelik, A; Hugyecz, M; Janka, Z; Kálmán, J; Kása, P; Pákáski, M, 2005) |
| "Thirty-eight patients with Alzheimer's disease (AD), 13 patients with vascular dementia, and 40 healthy controls were included in the study." | 1.31 | Serotonin 5-HT2A receptor binding in platelets from patients with Alzheimer's disease or vascular dementia. ( Eriksson, S; Mjörndal, T; Spigset, O; Wilhelmsson, C, 2000) |
| "Citalopram was well tolerated by 13 of the patients, and 9 had a clinically impressive response." | 1.30 | An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations. ( Burgio, LD; Kirshner, MA; Mulsant, BH; Pollock, BG; Rosen, J; Shuster, K; Sweet, R, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (1.23) | 18.7374 |
| 1990's | 8 (9.88) | 18.2507 |
| 2000's | 12 (14.81) | 29.6817 |
| 2010's | 50 (61.73) | 24.3611 |
| 2020's | 10 (12.35) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, W | 1 |
| Wang, H | 2 |
| Li, X | 3 |
| Xu, Y | 2 |
| Zhang, J | 1 |
| Wang, W | 1 |
| Gong, Q | 2 |
| Qiu, X | 1 |
| Zhu, J | 2 |
| Mao, F | 2 |
| Zhang, H | 2 |
| Li, J | 3 |
| Rodríguez-Lavado, J | 1 |
| Gallardo-Garrido, C | 1 |
| Mallea, M | 1 |
| Bustos, V | 1 |
| Osorio, R | 1 |
| Hödar-Salazar, M | 1 |
| Chung, H | 1 |
| Araya-Maturana, R | 1 |
| Lorca, M | 1 |
| Pessoa-Mahana, CD | 1 |
| Mella-Raipán, J | 1 |
| Saitz, C | 1 |
| Jaque, P | 1 |
| Reyes-Parada, M | 1 |
| Iturriaga-Vásquez, P | 1 |
| Pessoa-Mahana, H | 1 |
| Huang, Y | 1 |
| Fu, Y | 1 |
| Huang, J | 1 |
| You, H | 1 |
| Zhang, D | 2 |
| Elsworthy, RJ | 1 |
| Crowe, JA | 1 |
| King, MC | 1 |
| Dunleavy, C | 1 |
| Fisher, E | 1 |
| Ludlam, A | 1 |
| Parri, HR | 1 |
| Hill, EJ | 1 |
| Aldred, S | 1 |
| Ehrhardt, S | 1 |
| Porsteinsson, AP | 16 |
| Munro, CA | 12 |
| Rosenberg, PB | 14 |
| Pollock, BG | 17 |
| Devanand, DP | 14 |
| Mintzer, J | 2 |
| Rajji, TK | 1 |
| Ismail, Z | 5 |
| Schneider, LS | 16 |
| Baksh, SN | 1 |
| Drye, LT | 14 |
| Avramopoulos, D | 4 |
| Shade, DM | 12 |
| Lyketsos, CG | 16 |
| Takemoto, M | 1 |
| Ohta, Y | 1 |
| Hishikawa, N | 1 |
| Yamashita, T | 1 |
| Nomura, E | 1 |
| Tsunoda, K | 1 |
| Sasaki, R | 1 |
| Tadokoro, K | 1 |
| Matsumoto, N | 1 |
| Omote, Y | 1 |
| Abe, K | 1 |
| Wang, YJ | 2 |
| Gong, WG | 2 |
| Ren, QG | 2 |
| Zhang, ZJ | 2 |
| Cirrito, JR | 4 |
| Wallace, CE | 1 |
| Yan, P | 2 |
| Davis, TA | 1 |
| Gardiner, WD | 1 |
| Doherty, BM | 1 |
| King, D | 1 |
| Yuede, CM | 1 |
| Lee, JM | 4 |
| Sheline, YI | 4 |
| Oliveira, LF | 1 |
| Camargos, EF | 1 |
| Martini, LLL | 1 |
| Machado, FV | 1 |
| Novaes, MRCG | 1 |
| Smith, GS | 2 |
| Kuwabara, H | 1 |
| Nandi, A | 1 |
| Gould, NF | 1 |
| Nassery, N | 1 |
| Savonenko, A | 1 |
| Joo, JH | 1 |
| Kraut, M | 1 |
| Brasic, J | 1 |
| Holt, DP | 1 |
| Hall, AW | 1 |
| Mathews, WB | 1 |
| Dannals, RF | 1 |
| Workman, CI | 1 |
| Reddy, AP | 2 |
| Yin, X | 2 |
| Sawant, N | 2 |
| Reddy, PH | 2 |
| Morton, H | 1 |
| Kshirsagar, S | 1 |
| Bunquin, LE | 1 |
| Charu, V | 1 |
| Rein, L | 2 |
| Shade, D | 2 |
| Frangakis, CE | 1 |
| Viscogliosi, G | 2 |
| Chiriac, IM | 2 |
| Ettorre, E | 2 |
| Bartels, C | 1 |
| Wagner, M | 1 |
| Wolfsgruber, S | 1 |
| Ehrenreich, H | 1 |
| Schneider, A | 1 |
| Zhang, Q | 1 |
| Yang, C | 1 |
| Liu, T | 1 |
| Liu, L | 1 |
| Li, F | 1 |
| Cai, Y | 1 |
| Lv, K | 1 |
| Gao, J | 1 |
| Sun, D | 1 |
| Xu, H | 1 |
| Yang, Q | 1 |
| Fan, X | 1 |
| Wu, C | 1 |
| Sun, JJ | 1 |
| Zhou, H | 1 |
| Tao, Y | 1 |
| Peters, ME | 3 |
| Mintzer, JE | 12 |
| Weintraub, D | 13 |
| Yesavage, J | 11 |
| Ragab, GH | 1 |
| Bahgat, EA | 1 |
| Klaassens, BL | 1 |
| van Gerven, JMA | 1 |
| Klaassen, ES | 1 |
| van der Grond, J | 1 |
| Rombouts, SARB | 1 |
| Aga, VM | 1 |
| Small, GW | 2 |
| Frangakis, C | 7 |
| Marano, C | 5 |
| Meinert, CL | 5 |
| Pelton, G | 6 |
| Rabins, PV | 7 |
| Underwood, BR | 1 |
| Fox, C | 1 |
| West, T | 2 |
| Yarasheski, K | 2 |
| Swarm, R | 1 |
| Jasielec, MS | 2 |
| Fisher, JR | 1 |
| Ficker, WD | 1 |
| Xiong, C | 2 |
| Frederiksen, C | 2 |
| Grzelak, MV | 2 |
| Chott, R | 1 |
| Bateman, RJ | 2 |
| Morris, JC | 3 |
| Mintun, MA | 2 |
| Spragg, D | 1 |
| Tanskanen, A | 1 |
| Taipale, H | 1 |
| Koponen, M | 1 |
| Tolppanen, AM | 1 |
| Hartikainen, S | 1 |
| Ahonen, R | 1 |
| Tiihonen, J | 1 |
| Keltz, MA | 1 |
| Smith, JS | 1 |
| Sambeth, A | 1 |
| Riedel, WJ | 1 |
| Klinkenberg, I | 1 |
| Kähkönen, S | 1 |
| Blokland, A | 1 |
| Soysal, P | 1 |
| Isik, AT | 1 |
| Emilsson, JF | 1 |
| Andreasson, U | 1 |
| Blennow, K | 1 |
| Eriksson, E | 1 |
| Zetterberg, H | 1 |
| Hettinger, JC | 1 |
| Tripoli, DL | 1 |
| Antonsdottir, IM | 1 |
| Smith, J | 1 |
| Keltz, M | 1 |
| Cummings, J | 1 |
| Zhong, K | 1 |
| Vaidya, V | 1 |
| Newell, J | 2 |
| Žmuc Veranič, L | 1 |
| Pregelj, P | 1 |
| Jerin, A | 1 |
| Choe, YM | 1 |
| Kim, KW | 1 |
| Jhoo, JH | 1 |
| Ryu, SH | 1 |
| Seo, EH | 1 |
| Sohn, BK | 1 |
| Byun, MS | 1 |
| Bak, JH | 1 |
| Yun, HJ | 1 |
| Han, MI | 1 |
| Woo, JI | 1 |
| Lee, DY | 1 |
| Akil, A | 1 |
| Bies, RR | 1 |
| Yesavage, JA | 2 |
| Taylor, JL | 2 |
| Kraemer, HC | 1 |
| Friedman, L | 2 |
| Madore, M | 1 |
| Chao, SZ | 1 |
| Noda, A | 2 |
| Marano, CM | 1 |
| Mulsant, BH | 3 |
| Newell, JA | 2 |
| Pawluczyk, S | 1 |
| Leonpacher, AK | 1 |
| Makino, KM | 1 |
| Lazzeroni, LC | 1 |
| Leoutsakos, JS | 1 |
| Kinoshita, LM | 1 |
| Perlow, MJ | 1 |
| Ho, T | 1 |
| Schantz, O | 1 |
| Lyketsos, C | 1 |
| Bies, R | 1 |
| Ma, L | 1 |
| Wen, C | 1 |
| Chen, C | 1 |
| Shen, S | 1 |
| Yang, J | 1 |
| Levada, OA | 1 |
| Cherednichenko, NV | 1 |
| Trailin, AV | 1 |
| Troyan, AS | 1 |
| Herrmann, N | 1 |
| An, H | 1 |
| Choi, B | 1 |
| Park, KW | 1 |
| Kim, DH | 1 |
| Yang, DW | 1 |
| Hong, CH | 1 |
| Kim, SY | 1 |
| Han, SH | 1 |
| Kálmán, J | 3 |
| Tosto, G | 1 |
| Talarico, G | 1 |
| Lenzi, GL | 1 |
| Bruno, G | 1 |
| Nikisch, G | 1 |
| Wiedemann, G | 1 |
| Kiessling, B | 1 |
| Hertel, A | 1 |
| Kramer, E | 1 |
| Ma, Y | 1 |
| Hermann, CR | 1 |
| Dhawan, V | 1 |
| Chaly, T | 1 |
| Eidelberg, D | 1 |
| Siddique, H | 1 |
| Hynan, LS | 1 |
| Weiner, MF | 1 |
| Rozzini, L | 1 |
| Chilovi, BV | 1 |
| Conti, M | 1 |
| Bertoletti, E | 1 |
| Zanetti, M | 1 |
| Trabucchi, M | 1 |
| Padovani, A | 1 |
| Yee, AH | 1 |
| Wijdicks, EF | 1 |
| Lai, MK | 2 |
| Tsang, SW | 2 |
| Esiri, MM | 2 |
| Francis, PT | 2 |
| Wong, PT | 2 |
| Chen, CP | 2 |
| Barak, Y | 1 |
| Plopski, I | 1 |
| Tadger, S | 1 |
| Paleacu, D | 1 |
| Disabato, BM | 1 |
| Restivo, JL | 1 |
| Verges, DK | 1 |
| Goebel, WD | 1 |
| Sathyan, A | 1 |
| Hayreh, D | 1 |
| D'Angelo, G | 1 |
| Benzinger, T | 1 |
| Yoon, H | 1 |
| Kim, J | 1 |
| Pomara, N | 1 |
| Bruno, D | 1 |
| Hellen, F | 1 |
| Supprian, T | 1 |
| Salamon, T | 1 |
| Lange-Asschenfeldt, C | 1 |
| Spence, I | 1 |
| Keene, J | 1 |
| Hope, T | 1 |
| Palotás, A | 1 |
| Puskás, LG | 1 |
| Kitajka, K | 1 |
| Palotás, M | 1 |
| Molnár, J | 1 |
| Pákáski, M | 2 |
| Janka, Z | 2 |
| Penke, B | 1 |
| Bjelik, A | 1 |
| Hugyecz, M | 1 |
| Kása, P | 1 |
| Rao, V | 1 |
| Spiro, JR | 1 |
| Lee, HB | 1 |
| Rosenblatt, A | 1 |
| Elgorashi, EE | 1 |
| Stafford, GI | 1 |
| Jäger, AK | 1 |
| van Staden, J | 1 |
| Leblhuber, F | 1 |
| Tohgi, H | 1 |
| Abe, T | 1 |
| Takahashi, S | 1 |
| Saheki, M | 1 |
| Kimura, M | 1 |
| Ragneskog, H | 1 |
| Eriksson, S | 2 |
| Karlsson, I | 2 |
| Gottfries, CG | 5 |
| Sweet, R | 1 |
| Burgio, LD | 1 |
| Kirshner, MA | 1 |
| Shuster, K | 1 |
| Rosen, J | 1 |
| Spigset, O | 1 |
| Wilhelmsson, C | 1 |
| Mjörndal, T | 1 |
| Tariot, PN | 1 |
| Dagerman, KS | 1 |
| Davis, KL | 1 |
| Davis, S | 1 |
| Hsiao, JK | 1 |
| Jeste, DV | 1 |
| Katz, IR | 1 |
| Olin, JT | 1 |
| Rosenheck, RA | 1 |
| Lebowitz, B | 1 |
| Lieberman, JA | 1 |
| Nyth, AL | 3 |
| D'Amato, RJ | 1 |
| Zweig, RM | 1 |
| Whitehouse, PJ | 1 |
| Wenk, GL | 1 |
| Singer, HS | 1 |
| Mayeux, R | 1 |
| Price, DL | 1 |
| Snyder, SH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Escitalopram for Agitation in Alzheimer's Disease[NCT03108846] | Phase 3 | 392 participants (Anticipated) | Interventional | 2018-01-03 | Recruiting | ||
| Predictors of Response to Insomnia Treatments for Gulf War Veterans[NCT03208049] | 50 participants (Actual) | Interventional | 2017-08-01 | Completed | |||
| A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease[NCT00898807] | Phase 3 | 186 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Alzheimer's Disease (CATIE Alzheimer's Disease Trial)[NCT00015548] | 450 participants | Interventional | 2001-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 27.7 |
| Placebo and Psychosocial Intervention | 28.7 |
"Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from marked improvement(1), no change(4), and marked worsening(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7." (NCT00898807)
Timeframe: Baseline to 9 weeks
| Intervention | percentage moderate/marked improvement (Number) |
|---|---|
| Citalopram and Psychosocial Intervention | 40 |
| Placebo and Psychosocial Intervention | 26 |
NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 4.33 |
| Placebo and Psychosocial Intervention | 5.26 |
NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Citalopram and Psychosocial Intervention | 7.8 |
| Placebo and Psychosocial Intervention | 8.0 |
6 reviews available for citalopram and Alzheimer Disease
| Article | Year |
|---|---|
When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram.
Topics: Aged; Alzheimer Disease; Citalopram; Female; Humans; Mental Status and Dementia Tests; Psychomotor A | 2019 |
Advancements in the treatment of agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Cannabinoid Receptor Agonists; Cannabinoids; Citalopram; Clinical Trials, Phase I | 2015 |
Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer's Disease.
Topics: Alzheimer Disease; Apathy; Citalopram; Clinical Trials as Topic; Cognition Disorders; Humans; Mental | 2015 |
[Genomical and metabolomical abnormalities in Alzheimer disease and in experimental models].
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antidepressive Agents; Apolipoprotein E4 | 2008 |
Treatment of depression in elderly patients with and without dementia disorders.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia; Dementia, Vascular; Depressive Disorder; Humans; Neur | 1992 |
Disturbance of the 5-hydroxytryptamine metabolism in brains from patients with Alzheimer's dementia.
Topics: Alzheimer Disease; Brain; Cadaver; Citalopram; Humans; Neurosecretory Systems; Serotonin | 1990 |
26 trials available for citalopram and Alzheimer Disease
| Article | Year |
|---|---|
Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Citalopram; Double-Blind Method; Female; Humans; Male; P | 2019 |
The Efficacy of Sertraline, Escitalopram, and Nicergoline in the Treatment of Depression and Apathy in Alzheimer's Disease: The Okayama Depression and Apathy Project (ODAP).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Apathy; Citalopram; Depression; F | 2020 |
Efficacy and Safety of Citalopram Compared to Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Citalopram; | 2017 |
Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Behavioral Symptoms; Citalopram; Cross-Sectiona | 2018 |
Cholinergic and serotonergic modulation of resting state functional brain connectivity in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebellum; Cerebral Cortex; Cholinesterase Inhibitors; | 2019 |
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Caregi | 2014 |
An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice.
Topics: Adult; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antidepressive Agents; Brain; Cit | 2014 |
Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Cardiotoxicity | 2014 |
Biperiden selectively induces memory impairment in healthy volunteers: no interaction with citalopram.
Topics: Adult; Alzheimer Disease; Attention; Biperiden; Citalopram; Cross-Over Studies; Double-Blind Method; | 2015 |
Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Citalopram; Double-Blind Method; Female; Humans; Male; P | 2015 |
Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents; Apolipoproteins E; Brain-Derived | 2016 |
Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive A | 2015 |
Multicenter, randomized, placebo-controlled, double-blind clinical trial of escitalopram on the progression-delaying effects in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Brain; Citalop | 2016 |
Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Citalopram; Double-Blind Method; Humans; Hypnotics and Sedatives; Outcome Assessm | 2016 |
Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive Agents, Second-Generation; Ci | 2016 |
Effects of Citalopram on Neuropsychiatric Symptoms in Alzheimer's Dementia: Evidence From the CitAD Study.
Topics: Alzheimer Disease; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Delusions; Female; | 2016 |
R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia; Female; Humans; Isomerism; Male; Psychiatric Status R | 2016 |
The Effect of Escitalopram on Mood and Cognition in Depressive Alzheimer's Disease Subjects.
Topics: Affect; Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Citalo | 2017 |
Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Citalopram; Double-Blind Method; Female; Humans; Male | 2011 |
Citalopram for agitation in Alzheimer's disease: design and methods.
Topics: Alzheimer Disease; Citalopram; Cognitive Behavioral Therapy; Double-Blind Method; Female; Follow-Up | 2012 |
An open-label study of escitalopram (Lexapro) for the treatment of 'Depression of Alzheimer's disease' (dAD).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Citalopram; De | 2006 |
[Citalopram in treatment of behavioral disorders in demented patients].
Topics: Affective Symptoms; Aged; Aged, 80 and over; Alzheimer Disease; Citalopram; Dementia; Double-Blind M | 1994 |
Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor.
Topics: Aged; Alzheimer Disease; Citalopram; Dementia, Vascular; Humans; Indoles; Kynurenine; Selective Sero | 1995 |
National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology.
Topics: Aged; Algorithms; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Citalopram; Cost-Benefit | 2001 |
The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Citalopram; Dementia, Multi-Infarct; Double-Blind Metho | 1990 |
Effect of citalopram, a selective 5-HT reuptake blocker, in emotionally disturbed patients with dementia.
Topics: Alzheimer Disease; Citalopram; Dementia, Vascular; Double-Blind Method; Humans; Mental Disorders; Pl | 1991 |
49 other studies available for citalopram and Alzheimer Disease
| Article | Year |
|---|---|
Design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cholin | 2018 |
Synthesis, in vitro evaluation and molecular docking of a new class of indolylpropyl benzamidopiperazines as dual AChE and SERT ligands for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents; Cell | 2020 |
The novel therapeutic strategy of vilazodone-donepezil chimeras as potent triple-target ligands for the potential treatment of Alzheimer's disease with comorbid depression.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antidepressive Agents; Binding Sites; Brain; Choli | 2022 |
The effect of citalopram treatment on amyloid-β precursor protein processing and oxidative stress in human hNSC-derived neurons.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2022 |
Escitalopram Alleviates Alzheimer's Disease-Type Tau Pathologies in the Aged P301L Tau Transgenic Mice.
Topics: Aging; Alzheimer Disease; Animals; Citalopram; Humans; Injections, Intraperitoneal; Male; Mice; Mice | 2020 |
Effect of escitalopram on Aβ levels and plaque load in an Alzheimer mouse model.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Citalopram | 2020 |
Use of psychotropic agents to treat agitation and aggression in Brazilian patients with Alzheimer's disease: A naturalistic and multicenter study.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive Agents; Antipsychotic Agents; | 2021 |
Molecular imaging of beta-amyloid deposition in late-life depression.
Topics: Age Factors; Aged; Alzheimer Disease; Amyloid beta-Peptides; Antidepressive Agents, Second-Generatio | 2021 |
Protective effects of antidepressant citalopram against abnormal APP processing and amyloid beta-induced mitochondrial dynamics, biogenesis, mitophagy and synaptic toxicities in Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Autophagy; Citalo | 2021 |
Selective serotonin reuptake inhibitor citalopram ameliorates cognitive decline and protects against amyloid beta-induced mitochondrial dynamics, biogenesis, autophagy, mitophagy and synaptic toxicities in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Autophagy; Citalo | 2021 |
Characterizing Highly Benefited Patients in Randomized Clinical Trials.
Topics: Alzheimer Disease; Citalopram; Humans; Physicians; Psychomotor Agitation; Randomized Controlled Tria | 2017 |
Efficacy and Safety of Citalopram Compared With Atypical Antipsychotics on Agitation in Nursing Home Residents With Alzheimer Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Citalopram; Delirium; Humans; Nursing Homes; Psychomotor Ag | 2018 |
Impact of SSRI Therapy on Risk of Conversion From Mild Cognitive Impairment to Alzheimer's Dementia in Individuals With Previous Depression.
Topics: Aged; Alzheimer Disease; Citalopram; Cognitive Dysfunction; Depression; Humans; Kaplan-Meier Estimat | 2018 |
Citalopram restores short-term memory deficit and non-cognitive behaviors in APP/PS1 mice while halting the advance of Alzheimer's disease-like pathology.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Cerebral Cortex; | 2018 |
Escitalopram alleviates stress-induced Alzheimer's disease-like tau pathologies and cognitive deficits by reducing hypothalamic-pituitary-adrenal axis reactivity and insulin/GSK-3β signal pathway activity.
Topics: Alzheimer Disease; Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; C | 2018 |
Development of bioanalytical HPLC method for simultaneous determination of the antialzhiemer, donepezil hydrochloride and the antidepressant, citalopram hydrobromide in raw materials, spiked human plasma and tablets dosage form.
Topics: Alzheimer Disease; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; C | 2019 |
Commentary on "When and How to Treat Agitation in Alzheimer's Disease Dementia With Citalopram and Escitalopram".
Topics: Alzheimer Disease; Anxiety; Citalopram; Dementia; Humans; Psychomotor Agitation | 2019 |
Treating dementia and agitation.
Topics: Alzheimer Disease; Citalopram; Female; Humans; Male; Psychomotor Agitation; Selective Serotonin Reup | 2014 |
Citalopram decreases agitation in the context of Alzheimer's disease, but at doses higher than those commonly prescribed and at the expense of side effects.
Topics: Alzheimer Disease; Citalopram; Female; Humans; Male; Psychomotor Agitation; Selective Serotonin Reup | 2014 |
Calming Alzheimer's agitation: a promising drug.
Topics: Activities of Daily Living; Alzheimer Disease; Antidepressive Agents, Second-Generation; Citalopram; | 2014 |
From prescriptions to drug use periods - things to notice.
Topics: Alzheimer Disease; Citalopram; Diuretics; Dose-Response Relationship, Drug; Drug Labeling; Drug Pres | 2014 |
Role of citalopram in the treatment of agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Citalopram; Humans; Multicenter Studies as Topic; Psychomotor Agitation; Randomiz | 2014 |
Severe hyponatremia due to escitalopram treatment in an elderly adult with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Citalopram; Female; Humans; Hyponatremia; Selective Serotonin Reuptake Inhi | 2014 |
Comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice".
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antidepressive Agents; Citalopram; Femal | 2014 |
Reply to comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice".
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Antidepressive Agents; Citalopram; Femal | 2014 |
Treating agitation and aggression in patients with Alzheimer's disease with escitalopram.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antidepressive Agents, Second-Generation; Ci | 2016 |
A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.
Topics: Aged; Aged, 80 and over; Aging; Algorithms; Alzheimer Disease; Antidepressive Agents; Citalopram; Do | 2016 |
Principal components analysis of agitation outcomes in Alzheimer's disease.
Topics: Alzheimer Disease; Citalopram; Humans; Principal Component Analysis; Psychiatric Status Rating Scale | 2016 |
Hepatotoxicity Associated with Donepezil in an Individual Taking Citalopram.
Topics: Aged, 80 and over; Alzheimer Disease; Antidepressive Agents, Second-Generation; Chemical and Drug In | 2016 |
Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Cont | 2016 |
Lack of clinically useful response predictors for treating aggression and agitation in Alzheimer's disease with citalopram.
Topics: Aggression; Alzheimer Disease; Citalopram; Humans; Psychomotor Agitation | 2016 |
Effect of citalopram in treating hypersexuality in an Alzheimer's disease case.
Topics: Alzheimer Disease; Brain; Citalopram; Cognition Disorders; Disease Progression; Donepezil; Fluorodeo | 2008 |
[Familial Alzheimer's disease with presenilin 2 N141I mutation. A case report].
Topics: Adult; Alzheimer Disease; Antidepressive Agents, Second-Generation; Brain; Citalopram; Codon; Donepe | 2008 |
Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Area Under Curve; Biomarkers; Brain; Case-Control Studies; Cholinesterase I | 2009 |
Effect of a serotonin reuptake inhibitor on irritability, apathy, and psychotic symptoms in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Citalopram; Delusions; Drug Therapy, Combination; Hallucina | 2009 |
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depr | 2010 |
A perfect storm in the emergency department.
Topics: Aged; Alzheimer Disease; Citalopram; Drug Therapy, Combination; Female; Humans; Iatrogenic Disease; | 2010 |
Differential involvement of hippocampal serotonin1A receptors and re-uptake sites in non-cognitive behaviors of Alzheimer's disease.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Aged; Aged, 80 and over; Alzheimer Disease; Autopsy; Binding | 2011 |
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Aniline Compounds; Animals; Antidepressive Agents, Second- | 2011 |
Potential effects of the APOE epsilon2 allele and of family history of Alzheimer's disease on brain amyloid-β in normal elderly.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antidepressive Agents, Second-Generation; Brain; | 2011 |
Resumption of food and fluid intake in Alzheimer's disease with severe apathy following intravenous citalopram.
Topics: Alzheimer Disease; Apathy; Citalopram; Drinking; Eating; Female; Humans; Injections, Intravenous; Mi | 2012 |
Serotonin transporters are preserved in the neocortex of anxious Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Analysis of Variance; Anxiety; Carrier Proteins | 2003 |
The effect of citalopram on gene expression profile of Alzheimer lymphocytes.
Topics: Aged; Alzheimer Disease; Cell Adhesion; Citalopram; Cytoskeleton; Female; Gene Expression Profiling; | 2004 |
Imipramine and citalopram facilitate amyloid precursor protein secretion in vitro.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Antidepressive Ag | 2005 |
Inhibition of [3H]citalopram binding to the rat brain serotonin transporter by Amaryllidaceae alkaloids.
Topics: Alkaloids; Alzheimer Disease; Animals; Antidepressive Agents; Brain; Citalopram; Inhibitory Concentr | 2006 |
Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram.
Topics: Affective Symptoms; Aged; Alzheimer Disease; Antidepressive Agents; Anxiety Disorders; Citalopram; C | 1996 |
An open pilot study of citalopram for behavioral disturbances of dementia. Plasma levels and real-time observations.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Biological Availability; Citalopram; Female; | 1997 |
Serotonin 5-HT2A receptor binding in platelets from patients with Alzheimer's disease or vascular dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; Blood Platelets; Case-Control Studies; Cital | 2000 |
Aminergic systems in Alzheimer's disease and Parkinson's disease.
Topics: Alzheimer Disease; Biogenic Amines; Brain; Choline O-Acetyltransferase; Citalopram; Humans; Imiprami | 1987 |